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Abstract
Objective: Review the molecular mechanisms of action, efficacy, and potential side effects associated with inhaled
corticosteroids (ICS) in children with persistent asthma.
Sources: Articles in English from MEDLINE. The following terms were used: corticosteroids, inhaled corticosteroids,
asthma, children, beclomethasone, fluticasone, budesonide, ciclesonide, growth, adrenal insufficiency, bone mineral
density, and oral candidiasis. Treatment guidelines, review articles, controlled trials, meta-analyses, and systematic
reviews evaluating the efficacy and the adverse events of treatment with ICS were selected.
Summary of the findings: In vivo and in vitro studies show that the available ICS have different pharmacokinetic
and pharmacodynamic properties that result in different action potentials. ICS also differ as to the systemic and local
side effects. The bioavailability of these products is essential in order to determine the incidence of side effects. In
general, ICS are capable of controlling asthma, reducing the number of exacerbations, medical consultations,
hospitalizations, and the need of oral corticosteroid (applications) bursts. Improvement can also be seen in pulmonary
function, especially in patients with recent onset asthma. The most documented adverse effect is transitory decrease
of growth rate.
Conclusions: ICS are the main anti-inflammatory agent used to treat persistent asthma. When administered in low
doses, they seem to be safe and effective. Patient monitoring allows for early detection of possible side effects associated
with ICS.
J Pediatr (Rio J). 2006;82(5 Suppl):S198-205: Children, asthma, inhaled corticosteroids, budesonide, beclomethasone,
fluticasone, ciclesonide.
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Introduction
Corticosteroids (CS) are used as anti-inflammatory
therapy in many diseases, including asthma. Chronic
inflammation is associated with increased expression of
multiple inflammatory genes, which are regulated by pro-
inflammatory transcription factors such as nuclear factor-
kappa beta (NF-κβ) and protein activator-1 (AP-1), which
bind and activate coactivator molecules (CBP, SRC-1,
TIF-2, p300/CBP). Transcription factors are activated in
all inflammatory diseases. Coactivators acetylate histones
(protein components of chromatin), inducing gene
transcription.
Molecular mechanisms of CS action
The anti-inflammatory action of CS is measured by
their binding to glucocorticoid receptors (GR) in the
cytoplasm. Cytoplasmic GRs generally bind to carrier
proteins such as the heat shock 90-kDa proteins (hsp90)
and the FK-binding protein that protects the receptor and
prevents it from being confined in the nucleus.1
Once bound to the GR, CS undergo structural changes
that lead to the dissociation of the carrier proteins,
exposing nuclear localization signals to the GR. This
results in the quick transport of the CS/GR complex into
the nucleus, where the complex binds to specific DNA
sequences in the gene promoter region (GRE). After
binding to receptors in the DNA, CS can promote or inhibit
gene expression through processes called transactivation
and transrepression, respectively. For example, CS
transactivate the beta-2 adrenergic receptor gene, the
lipocortine-1 gene, the interleucine (IL)-10 gene, and the
NF-κβ (Ικβ−α) inhibitor gene with anti-inflammatory actions.
CS also promote the synthesis of two proteins that affect
the inflammatory signal transduction pathway: the
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glucocorticoid-induced leucine-zipper protein (GILZ), which
inhibits NF-κβ and AP-12, and MAP kinase phosphatase-1
(MKP-1), which inhibits p38 MAP kinase. Meanwhile, most
of the genes that are transactivated by CS are likely to be
involved in side effects, including hypertension, edema,
hypocalemia, glaucoma, and diabetes.3
Through the mechanism of transrepression, the CS
inhibit the action of transcription factors AP-1 and
NF-κβ, decreasing the production of inflammatory
mediators, possibly by inhibiting histone acetylation (HAT).
With asthma, there is an increase in HAT activity and some
decrease in histone deacetylation (HDAC) activity, which
is restored by the treatment with CS. It is accepted that
this is the most important mechanism of action of CS on
inflammatory diseases.1,4
 CS inhibit the transcription of various cytokines and
chemokines that are relevant to inflammatory lung diseases,
including IL-1ß, TNF-α, GM-CSF, IL-4, IL-5, IL-8, and
eotaxine.5 Not only do CS block the synthesis of cytokines,
they also block cytokine effect by inhibiting the synthesis
of cytokine receptors such as the IL-2 receptor. CS reduce
the life span of eosynophyls and of lymphocytes.5
Treatment with CS is immunosuppressant and anti-
inflammatory, and it also promotes the differentiation of
regulatory T cells (CD25+CD4+) through a FOXP3-
dependent mechanism. The regulatory CD25+CD4+ T
cells represent a population of lymphocytes capable of
suppressing the immunological response. The FOXP3
marker is correlated with the expression of the anti-
inflammatory cytokine IL-10, and is a marker of the
activation of regulatory T cells.6
Dose vs. safety
All inhaled CS are absorbed systemically and have
dose-related adverse systemic effects. Systemic absorption
can occur directly through the lung surface or by swallowing
the drug.
Immediately after inhaling the CS with the aerosol
doser (pMDI), approximately 10 to 20% of the nominal
dose delivered is deposited on the lungs, while most of it
lodges on the oropharynx and is swallowed. After absorption
in the gastrointestinal tract, the drug passes through the
liver before entering the systemic circulation. Some CS,
especially budesonide (BUD) and fluticasone (FP), are
metabolized (89% and 99%, respectively) the first time
they pass through the liver. Therefore, after oral absorption,
they enter the systemic circulation as inactive
metabolites.7,8 Most drugs, however, are not efficiently
inactivated during first-pass metabolism, and enter the
systemic circulation without modifications, resulting in
extra-pulmonary side effects.
Deposition on the oropharynx and its undesirable local
and systemic effects are significantly reduced if the CS is
administered with large volume spacers. Washing the
mouth after using the metered dose or dry powder
inhalers is also recommended in order to reduce systemic
bioavailability (swallowed portion).9 It is important to not
that different CS are metabolized differently.
Beclomethasone dipropionate (BDP) is metabolized in the
form of beclomethasone monopropionate in many tissues,
including the lungs, but there is little information about the
formation and absorption of this metabolite in humans.
The dose of CS delivered to the lungs will also be
absorbed by the systemic circulation. Absorption through
the lung surface is quick, and if the drug is not locally
metabolized there could be extra-pulmonary effects,
especially with very high doses. Currently there are four
CS available for asthma treatment: BDP, BUD, FP, and
more recently ciclesonide (CIC). These inhaled CS differ
not only in terms of pharmacokinetic and pharmacodynamic
properties, but also in terms of potency.
CIC, considered to be a soft steroid, is activated only
in the lungs after being inhaled, which ensures fewer
adverse effects. CIC in itself is inactive, and needs to be
cleaved by specific pulmonary esterases to bind to the
GR.10 This CS has strong anti-inflammatory properties
and is practically biounavailable. It is a pro-drug without
direct activity and low affinity for GRs. Activated CIC is
quickly metabolized and transformed in inactive products.11
Inhalation devices
The efficacy of CS depends on the topical activity of the
drug that reaches the lungs, while the adverse effects
depend on oral deposition and on systemic activity. The
drugs systemic activity depends on the amount absorbed
by both the gastrointestinal tract and the lungs. The
amount of drug delivered to the lungs depends on inhalation
technique,12 on the type of inhaler used, with delivery of
different size particles,13 and on whether or not spacers
are used.
Each inhalation device, whether pMDI or dry powder
inhaler (DPI), requires specific techniques for suitable
intrapulmonary delivery.14 Inhalation devices are so
different from one another that the delivery characteristics
of one cannot be extrapolated to the others.14 The use of
spacers can alter the amount of breathable particles
(between 1 and 4 µm) that reach the lungs and decrease
oropharynx deposition, altering both the therapeutic
efficacy and the potential for systemic effects.15
In pMDI there is a current trend to replace
chlorofluorocarbon propellants with hydrofluoroalkane
due to their greater pulmonary deposition, greater
efficacy16 and absence of impact on the ozone layer.
Other factors that influence the use of pMDI include the
patients ability to coordinate the delivery of the drug
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Table 1 - Comparison of pharmacokinetic and pharmacodynamic parameters of inhaled corticosteroids (adapted from
Cerasoli11)
BDP = beclomethasone dipropionate, BMP = beclmethasone monopropionate, BUD = Budesonide, FP = fluticasone propionate, CIC = Ciclesonide,
MF = mometasone furoate, t1/2 = half-life, Vd = volume of distribution, Mod/high = moderate to high, V. high = very high.
Parameters BDP/BMP BUD FP CIC/desCIC MF
Oral bioavailability < 1% / 26% 11% < 1% < 1%/< 1% < 1%
Pulmonary deposition 51% BDP 28% 16% 52% CIC 14%
Local activation little none none yes none
Receptor binding affinity 53/1,345 935 1,800 12 / 1,200 1,235
Esterification none yes none yes none
Lipophilicity mod/high low high v. high/v. high
Protein binding: free fraction 87%:13% 88%:12% 90%:10% 99%:1% 98%:1%
t1/2, h 0.5/2.7 2.8 7.8 0.36/3.4 4.5
Vd, L 20/424 183 318 207/897
Clearance, L/h 15/120 84 69 152/228 53.5
and its inhalation. The use of valve spacers, however,
makes it possible for pMDI to be used even by children
younger than 2 years of age.
The dry powder inhaled devices (DPIs = diskhaler,
diskus, rotahaler, and turbuhaler) require deep inhalation
with an inhalation flow > 60 L/min14, which is only possible
for children older than 6 years of age.
Potency of the inhaled corticosteroids
It is difficult to compare the absolute potency levels of
the various inhaled CS considering that the available CS
have not been compared in a single study. The potency of
a CS or its capacity to produce a pharmacologic response
is based on its relative potency determined by various
measures such as cutaneous vasoconstriction assays
(human skin blanching), receptor binding affinity,
lipophilicity, and inhibition of inflammatory cells, mediators,
and cytokines. Available in vivo and in vitro measurements
of CS functional activity suggest the following relative
potencies: FP > BUD = BDP > triamcinolone acetonide
(TAA) = flunisolide (FLU).17 From a pharmacological point
of view, the differences in potency are relatively insignificant
unless they translate into clinical efficacy.
The activity of a drug depends on its pharmacokinetic
and pharmacodynamic properties. Pharmacokinetics
determines the concentration-time ratio at the application
site. Pharmacodynamics determines the relationship
between the concentration of the drug and its clinical
effects. A combination of these two parameters is
needed in order to determine the global effect of the
drug over time.18
The therapeutic index, or clinical efficacy, is the only
measurable parameter for comparing new inhaled CS or
the new CS/inhaler combination with the existing ones.
For that, it is necessary to consider the drugs
pharmacokinetics (e.g. affinity with receptor, plasma half-
life, distribution volume, plasma clearance, and first-pass
liver metabolism rate), pharmacodynamics (e.g. properties
of dose-response and duration of action), and the
characteristics of each inhalation device (e.g. distribution
of particle size, efficacy of pulmonary delivery, and usability)
(Table 1). The ideal CS should not only be effective, but
also safe, that is, it should have a high therapeutic index.
Since the same receptor mediates the effects of all
inhaled CS, the qualitative response resulting from the
occupation of GR is similar for all. Therefore, the
pharmacodynamics of inhaled CS depends exclusively
on receptor affinity. In order to ensure equivalent
effects, the differences in affinity can be compensated
by controlling the dose, that is, the concentration of the
drug at the GR binding site. Since the pharmacodynamics
of each inhaled CS depends only on the drugs relative
GR binding affinity, and because this difference in
affinity can be controlled by dose adjustments, the
greatest difference between different inhaled CS should
be due to their pharmacokinetic properties (Table 1).
The following aspects related to the pharmacokinetics of
inhaled CS are considered to be important: bioavailability,
clearance, distribution volume, half-life, time of
permanence in the lung tissue, lipid conjugation, protein
binding, and nature of the CS under consideration
(biologically active drug or pro-drug) (Table 1).
A discussion about the bioavailability of inhaled CS
should differentiate two types of bioavailabilities 
pulmonary and oral  which together make up the total
systemic bioavailability. Beclomethasone monopropionate
has the highest oral bioavailability (~25%), while FP and
the active product of CIC have insignificant oral
bioavailability.
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Dose Beclo/Budesonide Fluticasone Ciclesonide
Children Adults Children Adults Children Adults
Low < 200 < 400 < 100 < 200 80 < 160
Moderate 200 to 400 400 to 800 100 to 200 200 to 400 160 320
High > 400 > 800 > 200 > 400 > 320
Table 2 - Doses (µg/day) of inhaled corticosteroids
In order to reduce systemic adverse events, an inhaled
CS should be eliminated from the systemic circulation as
quickly as possible. All inhaled CS are quickly metabolized
by the liver (~90 L/h).19 The drugs that are primarily
present in tissues have low serum concentrations and
therefore large distribution volumes, while the drugs that
are primarily present in the blood present low distribution
volumes. FP and the two active pro-drug metabolites
present large distribution volumes, which means good
tissue penetration, in this case into lung tissue19 (Table 1).
Half-life is the time required for the drug concentration
to drop by 50%. Drugs with high clearance have short
half-lives, and drugs with large distribution volumes have
longer half-lives.19 Another way of measuring how long
the CS stays in the lung (pulmonary residence time) is by
calculating the percentage of the drug absorbed over time.
Consistent with its long half-life, PF is absorbed slowly,
with a significant amount remaining in the lungs 4 to 8
hours after inhalation. In contrast, BUD quickly disappears
in the lungs (Table 1).
Lipid conjugation is another important parameter to
evaluate the pharmacokinetics of ICS. Lipid-conjugated
ICS is retained in the lungs and is not absorbed by the
systemic circulation. The distinction between lipid
conjugation and lipophilicity is important. Drugs with high
lipophilicity frequently present a high degree of unspecific
binding to lipids and proteins, which results in their
widespread distribution in tissues. As a result of the large
distribution volume, drugs such as PF, which have high
lipophilicity, also have a long half-life (Table 1).
Protein binding is important because only CS-free
molecules can interact with GR; protein-bound molecules
are inactive. BDP, BUD, and FP have similar percentages
of free drug (~10%). The active product of CIC (des-CIC)
has a protein-binding level greater than 99%, which
results in a very low proportion of free drug in the
circulation in comparison to other ICS. As a result of this
high protein binding, less than 1% of des-CIC entering the
systemic circulation is available for potential adverse
systemic effects, in comparison to 10% or more for other
inhaled CS. Therefore, CIC produces significantly less
suppression than other ICS20 (Table 1).
Clinical efficacy
Three systematic reviews show that BDP, BUD, and FP
promote a significant improvement in pulmonary function
evaluated based on forced expiratory volume in the first
second (FEV1) and peak expiratory flow (PEF), lower
frequency of asthma exacerbations, improvement in the
symptoms, and less need of beta-2 agonists in any daily
dose, versus placebo21-23.
The determination of clinical efficacy is dependent on
the treatment time stipulated. The symptoms of asthma
can show a clear response after a few days, whereas
maximum improvement of pulmonary function may require
weeks. Furthermore, maximum improvement of bronchial
hyper-reactivity may take months after the treatment
with CS is begun. The results can also vary depending on
the CS dose, the severity of asthma at the start of therapy,
and on the exposures to allergens and infectious agents
during the study.
The standard doses of inhaled CS for adults and
children are listed in Table 2.
Some practical points could be indicated for ICS
management24:
 In cases of mild/moderate asthma, the dose-response
profile is not clear, and in general, the highest benefit
is obtained with low/moderate doses.
 With mild/moderate asthma, high doses of PF are
followed by a marked increase of side effects in the oral
cavity, with little improvement in terms of disease
control.
 For patients requiring ICS, a moderate initial dose is
just as effective as a high initial dose that is gradually
reduced along with clinical stabilization.
 Patients with chronic asthma, especially those that
frequently use CS either orally or systemically, benefit
from elevated doses of inhaled CS.
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A meta-analysis of 14 comparative clinical trials
demonstrated that half dose of FP (as compared to BUD
and BDP) was numerically superior in all the trials and
statistically superior in four of them when compared with
BUD and BDP. Therefore, despite the difficulties with
standardization, the trials suggest that when using pMDI,
FP is more effective than BDP, TAA, and BUD; however,
the efficacy of BUD with turbuhaler is similar to that of FP
delivered by pMDI or by diskhaler, and better than that of
BDP.25
Patients with moderate asthma reach similar levels of
asthma control with moderate or high doses of FP. High
doses of FP (more than 500 µg/day) are beneficial for
chronic patients. On CS-dependent asthmatics, significant
reductions can be obtained in the oral CS doses with
2,000 µg FP/day, which translates into an advantage in
terms of side effects26.
Corticosteroids and quality of life
CS improve performance at school and at work, and
reduce sleep disturbances associated with breathing
symptoms. They are more effective when begun days
before the exposure to allergens or irritants and should
be used regularly, for periods of time sufficient to keep
the patient clinically stable. The advantage of topical
applications is the lower occurrence of adverse systemic
effects. Nevertheless, all topical CS are systemically
absorbed and have a class effect of dose-dependent
adverse effects. Treatment should be adjusted so that
the minimum dose capable of promoting clinical stability
is used.
Adverse effects
The bioavailability of the new ICS is low and most of
them are dependent on the inhaled fraction that reaches
the systemic circulation after absorption through the
lungs. However, various factors are important to determine
the clinical and systemic effects and the therapeutic index
of the ICS: dose delivered, potency, deposition, receptor
affinity and local retention, distribution, clearance, and
the individual differences in the response to the GC. The
main adverse systemic effects of the ICS are as follows:
hypothalamic-pituitary-adrenal axis suppression, bone
mineral density, vertical growth, and ocular toxicity
(including subcapsular cataract and glaucoma).11,27
Hypothalamic-pituitary-adrenal axis suppression
The frequency of secondary adrenal insufficiency due
to the suppression of the hypothalamic-pituitary-adrenal
(HPA) axis resulting from ICS treatment is very low. A few
cases in children have been associated with long-term
treatment with PF.28 There is no consensus regarding the
suppressing action of ICS on the HPA axis, and the method
used to evaluate this suppression is one of the factors that
can affect the interpretation of results. Suppression can be
evaluated by 24-hour serial monitoring of serum cortisol
levels, by determination of nocturnal or 24-hour cortisol in
the urine, and by the adrenocorticotropic hormone (ACTH)
stimulation test . Further confounding factors are the
equivalence of the ICS doses used and the devices used.
A meta-analysis of studies carried out with adults
and children concluded that PF has significantly greater
adrenal suppressing potential when compared to BDP,
BUD or TAA.29
Patients in treatment with a low to moderate dose of
ICS (< 400 µg/day of BDP, BUD or TAA, or < 200 µg PF,
or 160 µg of CIC) usually do not present significant
changes in 24-hour plasma cortisol levels,30 in urine
cortisol, and in the response to the ACTH stimulation
test.31 However, suppression of the HPA axis has been
detected (without any clinical expression) when using
powder inhalation devices, which increase the amount of
drug that reaches the lung even in these lower doses.32
CIC, the most recent of the ICS available for clinical
use in children, has demonstrated efficacy in asthma
treatment and a better profile of side effects when
compared to other CS.33 Considered a pro-drug, CIC is
activated locally in the lung by pulmonary esterase
activity, which ensures high local concentration and
little gastrointestinal absorption. Because of its high
sensitivity to hepatic oxidases, CIC has a very short
plasma half-life, which reduces systemic exposure to
the active drug to a minimum.11 This low systemic
exposure has been shown in recent studies demonstrating
the absence of a relevant clinical effect on the HPA axis
even with high doses, such as 320 to 1,280 µg34.
In conclusion, treatment with low or moderate doses
(< 400 µg/d) of ICS is usually not associated with
suppression of the HPA axis in children. Because of this,
the routine monitoring of the HPA axis is not necessary,
unless there is evidence of growth suppression. On the
other hand, children with chronic asthma who receive high
doses of ICS or who have been receiving GC through other
routes (topical, intranasal) should have their morning
levels of plasma cortisol monitored periodically, even in
the absence of increased risk of HPA axis suppression. In
the presence of low levels, they should be submitted to the
ACTH stimulation test.19
Bone metabolism
Because CS increase reabsorption and decrease bone
formation, they can cause dose- and age-dependent
osteoporosis. Bone turnover is greater in children than in
adults. Bone mass/density acquisition begins in childhood
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and peaks in young adults. Many factors are identified as
capable of interfering with the content of bone mass: sex,
nutrition, hereditariness, endocrine factors, and physical
activity.
The effects of exogenous CS on bone can be evaluated
by biochemical markers of bone metabolism, bone
mineral density (BMD), or frequency of fractures. A
recent review of ICS effects on bone showed no evidence
of changes in bone markers or degradation in children
treated with ICS in standard doses.35 Moreover, elevated
doses may cause significant changes in the bone turnover
rate, but the occurrence of these changes during the
treatment, which his usually short-term, deserves further
studies.27
Asthmatic children treated with BUD (> 800 µg/day)
for longer than 18 months,36 or BUD (500 µg/day) for 4.5
years,32,37 or BDP (300-800 µg/day) for 2 years38 do not
present reduction of BMD when compared to those treated
with placebo or smaller doses of the respective ICS. In
wheezing infants, the use of an intermittent treatment
model with inhaled BUD (400 µg/day) did not determine
significant changes in BMD.39 In a recent review of the use
of ICS in children with asthma, none of the four trials
evaluating BMD presented a significant alteration.40
In light of the current studies, there is no evidence
that the long-term treatment of children with ICS in low
doses is associated with the reduction of BMD or with
increased risk of osteoporosis or fracture.41 However,
changes in the total bone mineral content in children
treated with high doses of BDP or BUD or PF have been
recently documented during 12 months of treatment.42,43
An experimental assay has documented the absence of
effect on bone metabolism with ciclesonide, even in
elevated doses.20
Linear growth
Growth is a complex, non-homogenous physiological
phenomenon that is influenced by many factors: genetics,
nutrition, hormones, and others. CS interfere with collagen
turnover and with the levels of somatomedin, the final
growth promoter, produced by human growth hormone;
therefore, these drugs may be associated with growth
deficit in children with asthma and long-term treatment
with ICS, especially in high doses.19 This interference is
more evident during fast growth phases (spurts) in
preschool years and puberty. Asthma, however, in and of
itself, can interfere with the growth rate.
To monitor growth rate, knemometry (measurement
of lower leg length) is useful to detect changes occurring
over a short period of time and stadiometry is useful to
detect changes over medium or long-term periods.
However, adult stature is the most adequate parameter.42
Current evidence shows that treatment with ICS
(medium/high doses) can induce delay in the growth
rate at the start of treatment with BDP19,21,44 or
BUD.19,22 However, this interference is transitory, since
there are no reports of an influence on the adult stature
of these patients.19 A few patients receiving higher
doses of BDP or BUD (> 750 µg/day) during 14 weeks
presented growth retardation.45 According to the United
States National Asthma Education and Prevention
Program, low or medium doses of ICS have the potential
to impact growth rate, but the effects are small, non-
progressive, and possibly reversible. Furthermore, the
adult height reached by asthmatic children with ICS
treatment is not different than that reached by non-
asthmatic children.46
A meta-analysis of 21 trials including 810 patients has
compared the stature reached in relation to the treatment
with inhaled or oral CS. There was slight growth impairment
in those treated with oral CS.47 The Childhood Asthma
Management Program (CAMP) compared the efficacy and
safety of long-term treatment (4 to 6 years) with BUD and
nedocromil sodium in children with mild to moderate
asthma. Treatment with BUD resulted in improved airway
reactivity, better control of asthma, and transitory reduction
in growth rate.48 A similar finding was reported by other
investigators.49
Treatment with PF was evaluated in children with
mild asthma, and no interference was observed.50 On
the other hand, Guilbert et al. evaluated 2 years of
treatment with PF (176 µg/day) in children aged 2 to 3
years old. In addition to clinical control during the active
treatment period, a reduction in growth rate, with
partial recovery during the follow-up period, was also
recorded.51 A recent double-blind, placebo-controlled
study with children treated with different doses of
inhaled ciclesonide did not document changes in either
lower leg growth rate or effects on the HAP axis.52,53
Ocular toxicity
The risk of subcapsular and nuclear cataract associated
with the use of ICS is not significant in pediatric patients
with asthma; however, it may be greater in the elderly.
Sufficient information concerning the differences in the
risk of cataract associated with the different ICS
formulations is not available.19,35
Local side effects
Local side effects include coughing during inhalation,
dry throat, hoarseness, dysphonia, and oral
candidiasis5.4,55 Oral hygiene after ICS use helps reduce
these dose-dependent effects. CIC offers a significantly
lower chance of local side effects since it is not activated
on the oral mucosa. The use of devices can also promote
less oropharyngeal deposition.54,55
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